Lysophosphatidic acid and cardiovascular disease: seeing is believing
- PMID: 23509404
- PMCID: PMC3622311
- DOI: 10.1194/jlr.E037887
Lysophosphatidic acid and cardiovascular disease: seeing is believing
Figures
Comment on
-
Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation.J Lipid Res. 2013 May;54(5):1265-74. doi: 10.1194/jlr.M032862. Epub 2013 Feb 10. J Lipid Res. 2013. PMID: 23396975 Free PMC article.
References
-
- Bot M., de Jager S. C., Macaleese L., Lagraauw H. M., van Berkel T. J., Quax P. H., Kuiper J., Heeren R. M., Biessen E. A., Bot I. 2013. Lysophosphatidic Acid Triggers Mast Cell-driven Atherosclerotic Plaque Destabilization by Increasing Vascular Inflammation. J. Lipid Res. 54: 1265–1274 - PMC - PubMed
-
- Siess W., Zangl K. J., Essler M., Bauer M., Brandl R., Corrinth C., Bittman R., Tigyi G., Aepfelbacher M. 1999. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 96: 6931–6936 - PMC - PubMed
-
- McIntyre T. M., Pontsler A. V., Silva A. R., St Hilaire A., Xu Y., Hinshaw J. C., Zimmerman G. A., Hama K., Aoki J., Arai H., et al. 2003. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA. 100: 131–136 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
